Skip to main content
. 2019 Oct 4;55(6):1223–1236. doi: 10.3892/ijo.2019.4891

Figure 1.

Figure 1

GHSROS is expressed at low levels in normal breast tissue and at higher levels in breast cancer (BCa). (A) GHSROS expression in clinical BCa (n=176) and N breast samples (n=16), as determined by RT-qPCR. *P≤0.05, Mann-Whitney-Wilcoxon test. (B) GHSROS expression stratified by clinical stage of BCa, as determined by RT-qPCR. N (n=16), stage I (n=35), stage II (n=74), stage III (n=57) and stage IV (n=10). *P≤0.05, Kruskal-Wallis with Dunn's post hoc test. (C) GHSROS expression in the MCF10A and HMLE normal-breast derived cell lines, and the MDA-MB-231, MCF-7, T-47D, BT474 and MDA-MB-453 BCa cell lines compared to the MCF-10A cell line, as determined by RT-qPCR. ***P≤0.001 vs. MCF-10A, one-way ANOVA with Dunnett's post hoc test. All experiments were performed independently three times (n=3) with three replicates per experiment (n=3). Data are presented as the mean ± standard error of the mean, and relative expression levels were determined using the comparative 2−ΔΔCq method. Samples were normalised using β-actin. BCa, breast cancer; GHSROS, growth hormone secretagogue receptor opposite strand; N, normal; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.